CLS Q1’22: Our Comments - Redeye

Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new commercial partners in the urology segment, three new clinical studies initiated as well as a pending 510(k) approval for the second generation of TRANBERG Thermal Therapy System with Thermoguide Workstation, the company has an interesting period ahead.

Länk till analysen i sin helhet: https://www.redeye.se/research/842723/cls-q122-our-comments?utm_source=finwire&utm_medium=RSS